| Filed On | Filing |
|---|---|
| 26 Oct 2026 | SCHEDULE 13G/A |
| 26 Oct 2026 | 6-K |
| 01 Oct 2026 | 6-K |
| 17 Sep 2026 | 6-K |
| 25 Aug 2026 | N-PX |
| 12 Aug 2026 |
Form 4: Sanofi, 10% owner · Latigo Biotherapeutics, Inc.
Received 672,778 shares by conversion |
| 12 Aug 2026 | Form 3: Sanofi, 10% owner · Latigo Biotherapeutics, Inc. |
| 07 Aug 2026 |
Form 4: Sanofi, 10% owner · Attovia Therapeutics Inc
Received 782,855 shares by conversion · Bought 300,000 shares ($5.1M) |
| 06 Aug 2026 | 6-K |
| 04 Aug 2026 | Form 3: Sanofi, 10% owner · Attovia Therapeutics Inc |
| 30 Jul 2026 | 6-K |
| 30 Jul 2026 | 6-K |
| 28 Jul 2026 | 13F-HR |
| 27 Jul 2026 | 6-K |
| 22 Jul 2026 | SCHEDULE 13G/A |
| 17 Jul 2026 | 6-K |
| 07 Jul 2026 | 6-K |
| 30 Jun 2026 | 11-K |
| 30 Jun 2026 | NT 11-K |
| 30 Jun 2026 | NT 11-K |
Loading...
